JMD
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hussein, M. R. A.-E.
Right arrow Articles by Wood, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hussein, M. R. A.-E.
Right arrow Articles by Wood, G. S.
JMD 2002, Vol. 4, No. 2
Copyright © 2002 American Society for Investigative Pathology & Association for Molecular Pathology

Molecular Aspects of Melanocytic Dysplastic Nevi

Mahmoud Rezk Abd-Elwahed Hussein and Gary Stewart Wood

From the Department of Medicine (Dermatology), University of Wisconsin and William S. Middleton Memorial Veteran Hospital, Madison, Wisconsin

Melanocytic dysplastic nevi were first described in both patients and their relatives who had one or several cutaneous malignant melanomas. Most of these dysplastic lesions are biologically stable, but some of them have severe histological atypia and can progress further to melanomas. Although several studies have suggested the etiological importance of dysplastic nevi in the development of melanomas, comprehensive reviews of the molecular changes in these dysplastic lesions are still scarce. To remedy this issue, this article analyzes the available molecular information about dysplastic nevi and provides the current state of knowledge regarding the karyotypic abnormalities of the melanoma/dysplastic nevus trait and the involvement of allelic loss, tumor suppressor genes, mismatch repair proteins, microsatellite instability, oncogenes, extracellular matrix proteins, and growth factors in the genesis of these lesions. These studies suggest that although some of these lesions represent "genetic dead-ends," others represent intermediate lesional steps in the melanoma tumorigenesis pathway.




This article has been cited by other articles:


Home page
 JCOHome page
D. L. Dai, M. Martinka, and G. Li
Prognostic Significance of Activated Akt Expression in Melanoma: A Clinicopathologic Study of 292 Cases
J. Clin. Oncol., March 1, 2005; 23(7): 1473 - 1482.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K S Culpepper, S R Granter, and P H McKee
My approach to atypical melanocytic lesions
J. Clin. Pathol., November 1, 2004; 57(11): 1121 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M R Hussein
Genetic pathways to melanoma tumorigenesis
J. Clin. Pathol., August 1, 2004; 57(8): 797 - 801.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society for Investigative Pathology and the Association for Molecular Pathology.